Abstract
Introduction
The adipokine leptin was primarily described as a satiety regulatory metabotropic hormone, mainly produced by adipocytes under physiological conditions. Recently, leptin and its receptors (ObRs) have been shown to be overexpressed in a variety of tissues including the myocardium under conditions of ischemia/reperfusion [1] [2] [3] . Several lines of evidence indicate that leptin has powerful cardiac effects [4] . Nevertheless, reports are divided on whether leptin has predominantly adverse or beneficial effects on the heart. [5] and to exert a direct hypertrophic effect [6] [7] [8] [9] [10] . Moreover, in vivo continuous infusion of leptin following myocardial infarction (MI) in mice causes eccentric dilation with increased systolic function [10] . In addition, Purdham et al. have recently shown that chronic ObR blockade by systemic injection of specific antibodies limits the development of post-infarct cardiac dysfunction in rats [11] . Conversely, blunting leptin signalling in mice through leptin deficiency or ObR deficiency is associated with progressive cardiac hypertrophy [12] and increased severity of cardiac dysfunction and remodelling after MI [13] . In addition, leptin has been shown to reduce infarct size in isolated perfused rat hearts [14] and to attenuate cardiac apoptosis after ischemia by increasing bcl-2 and survivin gene expression and by reducing caspase-3 activity [15] . Therefore, the cardiovascular effects of leptin are very complex, and translating basic research studies to human physiology is very difficult, particularly in this area of research.
Leptin has been shown to decrease cardiac function through a signal transducer and activator of transcription 3 (STAT-3)-nitricoxide-p38 mitogen-activated protein kinase (p38 MAPK)-dependent mechanism
Clinical data have reported that elevated circulating leptin levels are associated with greater risk of congestive heart failure and cardiovascular disease at least in elderly [16] . Moreover, it has been demonstrated that human serum leptin level reaches a peak value on the second day of hospitalization after MI [17] For each group, the same amount of cardiac extract from three different hearts were mixed and incubated with the membrane, as previously described [18] . Membranes were scanned and blot-intensities (arbitrary units) were measured using ImageJ 1.37. Optical density of each spot was expressed as a percentage of a specific positive internal standard (after subtraction of background).
Materials and methods

Reperfused MI
Cardiac leptin inhibition with antisense oligodeoxynucleotides
Specific anti-leptin AS ODN and inactive random ODN [Control ODN, nearly same length and guanine-cytosine (GC) content] were designed and manufactured by Biognostik (Antisense custom design kit, accession nЊ : MN-013076; Biognostik, Göttingen, Germany). AS ODN and Control ODN were stored in sterile phosphate buffer at 4ЊC until use.
Five days after coronary artery occlusion and reperfusion, rats were anaesthetized and ventilated. The fourth intercostal space was reopened and the heart was briefly exteriorized by digital pressure on the chest wall.
Control ODN or AS ODN (0.1 mM solution) was rapidly injected in the myocardial wall in the border of the infracted area. Each animal received five intramyocardial micro-injections of ODN solution (total injected volume: 0.15 ml). No mortality was observed during this protocol.
Echocardiographic follow-up
Two-dimensional targeted M-mode recording was obtained from the short axis view of the heart at the level of the papillary muscle using a 15-7 MHz probe (HP21380A; Agilent Technology, Philips Systèmes Médicaux, France) connected to a Helwett Packard Sonos 5500. TM-mode measurements of the LV end-diastolic (LVEDD) and LV end-systolic (LVESD) dimensions were made according to the recommendations formulated by the American Society of Echocardiography. The percentage of LV fractional shortening (LVFS) was calculated as LVFS (%) ϭ ([LVEDD -LVESD]/LVEDD) ϫ 100.
Ex vivo determination of LV pressure-volume curves
Seven or 77 days after the surgical induction of infarction, rats were anaesthetized with ketamine (50 mg/kg) and xylazine (10 mg/kg) and passive pressure-volume characteristics of the LV were evaluated post-mortem as previously described [20] . A saturated solution of potassium chloride was injected into the vena cava until the heart stopped. 
Results
Time course of changes in myocardial leptin content after reperfused MI
Myocardial leptin level, measured by cytokine array, progressively increased from day 3 after MI to reach a maximum (ϩ380% versus non-operated) at day 7, before returning to non-operated baseline level at day 10 ( Fig. 1) . Fig. 2A) Fig. 2B and C) . (Fig. 3A) . Myocardial IL-1␤ (Fig. 3B) and IL-6 (Fig. 3C) , measured by ELISA, (Fig. 4) Control ODN rats (Fig. 4A ).
Effects of cardiac leptin inhibition on after MI
, FITC-ODN injected hearts exhibited diffuse fluorescence as well as focal hot spots corresponding to the points of injection (
Myocardial leptin, measured by ELISA, was significantly reduced 7 days after the initial surgical protocol in AS ODNTreated rats compared to Control ODN-treated rats
were markedly reduced 7 days after reperfused infarction in the AS ODN-treated group compared to the Control ODN-treated group.
Echocardiographic measurements
In rats treated with Control ODNs, MI induced a rapid decrease in LV contractility
which slowed down after the second week after surgery, giving a characteristic exponential curve. The treatment with anti-leptin ODNs completely stopped the deterioration of LV contractility. As a consequence, 77 days after the initial reperfused infarction, LVFS (%) in AS ODN-treated rats was 80% higher than LVFS in
Pressure-volume curves
LV pressure-volume curves measured ex vivo in potassium arrested hearts are shown in Figure 5A . Pressure (Fig. 5B) .
Discussion
Our experimental model of temporary left coronary artery ligation in rats induces a transient increase in myocardial leptin level, 7 days after reperfused MI. The inhibition of this peak of leptin production by specific AS ODNs reduces the expression of cardiac pro-inflammatory cytokines IL-1␤ and IL-6 and markedly reduces LV dysfunction.
Leptin neutralization after myocardial infarction
Leptin has been shown to exert a negative inotropic effect on ventricular myocytes via increased nitric oxide production [5, 21] , as well as to induce cardiac hypertrophy [6, 12] . On this basis some authors have suggested that ObR blockade could reduce cardiac hypertrophy and improve post-infarct cardiac function [11] . Therefore, they have tested the effects of chronic systemic administration [11] . Although this study has reported beneficial effects of the treatment, its translation to the human pathology of infarction is very difficult for several reasons. First, if leptin contributes to post-infarct cardiac dysfunction and heart failure, it is probably via an autocrine or paracrine mechanism [4] . Therefore, the anti-leptin treatment should have been targeted to the heart to avoid any interference with the physiological endocrine activity of the hormone. Second, the treatment should have been limited in duration to the time period during which endogenously produced leptin exerts its autocrine or paracrine detrimental action to the heart. Contrarily to this previous systemic approach, our 
Fig. 2 Localization of ODNs two days after intramyocardial injection. Rats were subjected to reperfused MI. Control unlabelled ODNs or FITC-labelled ODNs were injected in the border of the infarct, five days after surgery. Two days after ODN injection, rats were killed and their hearts were placed under a fluorescence camera (EMCCD 512 ϫ 512 Hamamatsu Orca -Macro Fluo 512 ϫ 512) and illuminated at 488 nm (Cube FITC Leica). (A) Rat heart injected with Control unlabelled ODNs; Rat heart injected with FITC-labelled ODNs: left view (B), right view (C).
Fig. 3 Effect of antisense leptin inhibition on leptin, IL-1␤ and IL-6 myocardial levels, 7 days after reperfused MI. Leptin (A), IL-1␤ (B) and IL-6 (C) ELISA assays on six to seven hearts per group. Open bars: Control ODN-treated group; Full bars: AS ODN-treated group. Means Ϯ S.E.M. *P Ͻ 0.05 versus Control ODN-treated group. (daily i.v. injection) of anti-ObR antibodies, in a rat model of permanent coronary occlusion, over a time period of 4 weeks after MI
Leptin and proinflammatory cytokines
ObRs have been shown to be induced locally in the heart after a sequence of ischemia and reperfusion [1, 3] [18, 19, 23] . In addition, Berthonneche et al. [20] have demonstrated that some of these cytokines contribute significantly to the development of subsequent LV dysfunction and heart failure since their inhibition durably protects cardiac function after MI. A direct link between leptin and pro-inflammatory cytokine production has already been demonstrated in several experimental studies. Notably, leptin induces IL-1␤ and IL-6 in different cell types [24] [25] [26] [27] . In the rat model of reperfused MI, IL-6 and IL-1␤ are transiently over produced 8 days after surgery [18] contribute to LV dysfunction and subsequent heart failure, at least in part through the induction of pro-inflammatory cytokine expression.
Cardiac sources of leptin
The present study demonstrates that reperfused MI induces a transient increase in cardiac leptin content within the first week after surgery. Nevertheless, the cell types responsible for leptin production as well as the mechanisms by which leptin expression is induced still remain to be determined. Leptin is traditionally viewed as an adipocyte-released hormone with endocrine effects. Nevertheless, several peripheral tissues, including the heart, are known to produce leptin which can then exert autocrine or paracine activities [1, 7] . Several in vitro studies have demonstrated that cardiomyocytes are able to produce leptin under diverse conditions of stress. Nevertheless, under pathophysiological situations, other cell types such as pericardial (epicardial plus paracardial adipose tissue [28] ) and perivascular adipocytes, can significantly contribute to cardiac leptin production. In small rodents, pericardial fat is only present in obese animals and is limited to a localized area around the pericardium, without any direct contact with the cardiomyocytes [4] . Therefore, the pericardial adipose tissue is probably not significantly involved in the transient cardiac leptin expression that we have observed in our study. In pathological states, perivascular fat can also secrete a deleterious profile of adipokines, and leptin levels in this tissue are thought to increase [29] . Nevertheless, the fact that direct intramyocardial injections of anti-leptin ODNs totally abolished the overproduction of leptin in our study strongly suggests that the origin of leptin is within the myocardium rather than perivascular.
In conclusion, our study shows that transient production of leptin in the myocardium after reperfused MI, contributes to the development of LV dysfunction and subsequent heart failure, through an autocrine or paracrine mechanism. Moreover, our results suggest that the mechanism of action of leptin in this context might involve the overexpression of proinflammatory cytokines. 
